Therapeutics News

With a new pharmaceutical treatment option, my conversations with presbyopic patients have gotten a lot more exciting.

Reproxalap 0.25% ophthalmic solution achieved primary and secondary endpoints in a trial investigating treatment of dry eye disease, Aldeyra Therapeutics announced in a press release.

Once-daily fixed combination bimatoprost, timolol and brimonidine more effectively reduced peak IOP compared with a twice-daily regimen in patients with primary open-angle glaucoma, according to a study in the Journal of Glaucoma.

About a year ago, the ER called over to the eye clinic and said a patient had asked to be seen because he was having double vision.

NEW YORK – Either a prostaglandin or selective laser trabeculoplasty is an effective primary treatment for glaucoma, “but once you get past the primary therapy, there are 44,000 different combinations of glaucoma medications you can prescribe,” said a speaker here at Vision Expo East.

DENVER – Bilastine 0.6% ophthalmic solution was shown in a phase 3 trial to be comfortable and effective in patients with allergic conjunctivitis, Paul J. Gomes, of Ora Inc. said here at ARVO.

In the digital age, intermediate vision is extremely important when people are using screens for as many as 12 hours a day.

Orasis Pharmaceuticals announced that its phase 3 trials showed patients treated with CSF-1 achieved a statistically significant three-line or more gain in distance-corrected near visual acuity with no loss of distance visual acuity.

NEW YORK – A phase 3 FDA registration trial for Ocuphire Pharma’s Nyxol yielded positive topline results for the reversal of mydriasis, according to a company executive.

NEW ORLEANS – Orasis Pharmaceuticals has completed two phase 3 studies of its presbyopia candidate, CSF-1, CEO Elad Kedar said here at SECO 2022.